Wall Street Trader schreef op 30 juni 2020 11:16:
Thanks for the addition NielsjeB. It has an impact, but it's a limited impact. It's a reality of life.
Onno and his team has always been very ambitious and setting the bar high.
....
Filgotinib trials are halting enrollment because of patient safety concerns, but one could imagine that, if the drug is comes to market, those concerns would still be there. Are you having conversations about the challenges of giving this drug to patients in the rheumatoid arthritis community?VAN DE STOLPE: I'm sure those discussions are being held.
All the drugs in rheumatoid arthritis are challenging the immune system. So you are one among a class. I don't think that's going to be the big change. People who have disease want to be treated — and [though] there's an additional risk of infections, it's clear they are aware of that. I don't know if people with milder forms of rheumatoid arthritis are stopping using drugs. I really can't tell. But if you have severe rheumatoid arthritis, you will use a drug. And then you have to be extremely careful not to get infected with this virus, that's for sure.